8-K current report · filed Oct 6, 2026

Biomarin Pharmaceutical Inc (BMRN) 8-K Current Report: October 6, 2026

Item 2.02BMRN overview

Short answer

Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Alesta acquisition expected to add approximately $283 million of pre-tax IPR&D expense in Q3 2026.

Biomarin Pharmaceutical Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Alesta acquisition expected to add approximately $283 million of pre-tax IPR&D expense in Q3 2026
  • Q3 GAAP and Non-GAAP diluted EPS impact: approximately $1.50 unfavorable
  • Full-year 2026 Alesta charges estimated at approximately $320 million, including operating, transaction and transition costs
  • Full-year GAAP and Non-GAAP diluted EPS impact: approximately $1.55 unfavorable
  • Updated 2026 guidance expected with Q3 results, while preliminary estimates remain subject to closing procedures

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Biomarin Pharmaceutical Inc 8-K filings

Get the next BMRN 8-K as it lands

Follow BMRN for push alerts, or ask the research agent what this filing means.